Sangeeta N. Bhatia - Apr 8, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 8, 2022
Transactions value $
-$294,612
Form type
4
Date filed
4/12/2022, 04:05 PM
Previous filing
Jun 4, 2021
Next filing
May 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $240K +1.91K +36.74% $125.71 7.1K Apr 8, 2022 Direct
transaction VRTX Common Stock Sale -$534K -1.91K -26.87% $280.20 5.19K Apr 8, 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1.91K -100% $0.00* 0 Apr 8, 2022 Common Stock 1.91K $125.71 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.
F2 Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $280.20 (range $280.00 to $280.53).
F4 Fully vested.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney